CVR number 36499281
Industry 46.3890 Wholesale of other food, including fish, crustaceans and molluscs

TRIO PHARMA ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  3.7% 3.7% 3.7% 3.7% 3.7%  
Bankruptcy risk  31.0% 18.1% 19.6% 13.6% 8.7%  
Credit score (0-100)  1 8 5 16 27  
Credit rating  C B B BB BB  
Credit limit (kDKK)  -0.0 -0.0 0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Gross profit  84.5 361 11,577 -491 -289  
EBITDA  -335 -113 11,241 -868 -828  
EBIT  -339 -122 11,241 -868 -828  
Pre-tax profit (PTP)  -361.4 -151.8 11,199.8 -889.4 -871.8  
Net earnings  -361.4 -151.8 9,019.6 -889.4 -489.7  
Pre-tax profit without non-rec. items  -361 -152 11,200 -889 -872  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Tangible assets total  40.6 0.0 0.0 0.0 0.0  
Shareholders equity total  -1,111 -1,263 -43.6 -933 -1,423  
Interest-bearing liabilities  0.0 0.0 254 1,773 2,681  
Balance sheet total (assets)  321 301 241 896 1,296  
Net Debt  -15.3 -18.2 95.2 1,490 2,644  
 
See the entire balance sheet

Volume 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  84.5 361 11,577 -491 -289  
Gross profit growth  -36.9% 326.5% 3,110.8% 0.0% 41.3%  
Employees  1 1 2 2 1  
Employee growth %  0.0% 0.0% 100.0% 0.0% -50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  321 301 241 896 1,296  
Balance sheet change%  -5.9% -6.5% -19.9% 272.1% 44.7%  
Added value  -334.9 -113.2 11,240.6 -868.3 -827.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  36 -50 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 1.0 -1.0 -2.0  

Profitability 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -401.5% -33.9% 97.1% 176.7% 286.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -26.9% -8.2% 1,216.4% -82.2% -36.2%  
ROI %  0.0% 0.0% 8,851.4% -85.7% -37.0%  
ROE %  -109.0% -48.8% 3,332.2% -156.5% -44.7%  

Solidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  -77.6% -80.8% -15.3% -51.0% -52.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  4.6% 16.1% 0.8% -171.6% -319.4%  
Gearing %  0.0% 0.0% -582.1% -190.0% -188.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 32.2% 2.1% 2.2%  

Liquidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  0.1 0.1 0.8 0.2 0.2  
Current Ratio  0.2 0.2 0.8 0.5 0.5  
Cash and cash equivalent  15.3 18.2 158.8 282.3 37.2  

Capital use efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,156.6 -1,268.0 -48.8 -939.0 -1,427.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  0 0 0 0 0  
Added value / employee  -335 -113 5,620 -434 -828  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -335 -113 5,620 -434 -828  
EBIT / employee  -339 -122 5,620 -434 -828  
Net earnings / employee  -361 -152 4,510 -445 -490